Martin Tauschmann1,2, Janet M Allen1,2, Malgorzata E Wilinska1,2, Hood Thabit1, Carlo L Acerini2, David B Dunger1,2, Roman Hovorka3,2. 1. Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K. 2. Department of Paediatrics, University of Cambridge, Cambridge, U.K. 3. Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K. rh347@cam.ac.uk.
Abstract
OBJECTIVE: This study evaluated the feasibility, safety, and efficacy of day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes under free-living conditions. RESEARCH DESIGN AND METHODS: In an open-label randomized crossover study, 12 suboptimally controlled adolescents on insulin pump therapy (mean ±SD age 14.6 ± 3.1 years; HbA1c 69 ± 8 mmol/mol [8.5 ± 0.7%]; duration of diabetes 7.8 ± 3.5 years) underwent two 21-day periods in which hybrid closed-loop insulin delivery was compared with sensor-augmented insulin pump therapy in random order. During the closed-loop intervention, a model predictive algorithm automatically directed insulin delivery between meals and overnight. Participants used a bolus calculator to administer prandial boluses. RESULTS: The proportion of time that sensor glucose was in the target range (3.9-10 mmol/L; primary end point) was increased during the closed-loop intervention compared with sensor-augmented insulin pump therapy by 18.8 ± 9.8 percentage points (mean ± SD; P < 0.001), the mean sensor glucose level was reduced by 1.8 ± 1.3 mmol/L (P = 0.001), and the time spent above target was reduced by 19.3 ± 11.3 percentage points (P < 0.001). The time spent with sensor glucose levels below 3.9 mmol/L was low and comparable between interventions (median difference 0.4 [interquartile range -2.2 to 1.3] percentage points; P = 0.33). Improved glucose control during closed-loop was associated with increased variability of basal insulin delivery (P < 0.001) and an increase in the total daily insulin dose (53.5 [39.5-72.1] vs. 51.5 [37.6-64.3] units/day; P = 0.006). Participants expressed positive attitudes and experience with the closed-loop system. CONCLUSIONS:Free-living home use of day-and-night closed-loop in suboptimally controlled adolescents with type 1 diabetes is safe, feasible, and improves glucose control without increasing the risk of hypoglycemia. Larger and longer studies are warranted.
RCT Entities:
OBJECTIVE: This study evaluated the feasibility, safety, and efficacy of day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes under free-living conditions. RESEARCH DESIGN AND METHODS: In an open-label randomized crossover study, 12 suboptimally controlled adolescents on insulin pump therapy (mean ± SD age 14.6 ± 3.1 years; HbA1c 69 ± 8 mmol/mol [8.5 ± 0.7%]; duration of diabetes 7.8 ± 3.5 years) underwent two 21-day periods in which hybrid closed-loop insulin delivery was compared with sensor-augmented insulin pump therapy in random order. During the closed-loop intervention, a model predictive algorithm automatically directed insulin delivery between meals and overnight. Participants used a bolus calculator to administer prandial boluses. RESULTS: The proportion of time that sensor glucose was in the target range (3.9-10 mmol/L; primary end point) was increased during the closed-loop intervention compared with sensor-augmented insulin pump therapy by 18.8 ± 9.8 percentage points (mean ± SD; P < 0.001), the mean sensor glucose level was reduced by 1.8 ± 1.3 mmol/L (P = 0.001), and the time spent above target was reduced by 19.3 ± 11.3 percentage points (P < 0.001). The time spent with sensor glucose levels below 3.9 mmol/L was low and comparable between interventions (median difference 0.4 [interquartile range -2.2 to 1.3] percentage points; P = 0.33). Improved glucose control during closed-loop was associated with increased variability of basal insulin delivery (P < 0.001) and an increase in the total daily insulin dose (53.5 [39.5-72.1] vs. 51.5 [37.6-64.3] units/day; P = 0.006). Participants expressed positive attitudes and experience with the closed-loop system. CONCLUSIONS: Free-living home use of day-and-night closed-loop in suboptimally controlled adolescents with type 1 diabetes is safe, feasible, and improves glucose control without increasing the risk of hypoglycemia. Larger and longer studies are warranted.
Authors: Daniela Elleri; Janet M Allen; Martina Biagioni; Kavita Kumareswaran; Lalantha Leelarathna; Karen Caldwell; Marianna Nodale; Malgorzata E Wilinska; Carlo L Acerini; David B Dunger; Roman Hovorka Journal: Pediatr Diabetes Date: 2012-07-23 Impact factor: 4.866
Authors: Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane Journal: Diabetes Care Date: 2015-06 Impact factor: 19.112
Authors: Steven J Russell; Firas H El-Khatib; Manasi Sinha; Kendra L Magyar; Katherine McKeon; Laura G Goergen; Courtney Balliro; Mallory A Hillard; David M Nathan; Edward R Damiano Journal: N Engl J Med Date: 2014-06-15 Impact factor: 91.245
Authors: Richard M Bergenstal; David C Klonoff; Satish K Garg; Bruce W Bode; Melissa Meredith; Robert H Slover; Andrew J Ahmann; John B Welsh; Scott W Lee; Francine R Kaufman Journal: N Engl J Med Date: 2013-06-22 Impact factor: 91.245
Authors: Bruce A Buckingham; Dan Raghinaru; Fraser Cameron; B Wayne Bequette; H Peter Chase; David M Maahs; Robert Slover; R Paul Wadwa; Darrell M Wilson; Trang Ly; Tandy Aye; Irene Hramiak; Cheril Clarson; Robert Stein; Patricia H Gallego; John Lum; Judy Sibayan; Craig Kollman; Roy W Beck Journal: Diabetes Care Date: 2015-06-06 Impact factor: 19.112
Authors: Oana Maftei; Alexia S Pena; Thomas Sullivan; Timothy W Jones; Kim C Donaghue; Fergus J Cameron; Elizabeth Davis; Andrew Cotterill; Maria E Craig; Roger Gent; Neil Dalton; Denis Daneman; David Dunger; John Deanfield; Jenny J Couper Journal: Diabetes Care Date: 2014-07-28 Impact factor: 19.112
Authors: Molly L Tanenbaum; Rebecca N Adams; Monica S Lanning; Sarah J Hanes; Bianca I Agustin; Diana Naranjo; Korey K Hood Journal: J Diabetes Sci Technol Date: 2018-07-11
Authors: Klemen Dovc; Charlotte Boughton; Martin Tauschmann; Hood Thabit; Lia Bally; Janet M Allen; Carlo L Acerini; Sabine Arnolds; Carine de Beaufort; Richard M Bergenstal; Fiona Campbell; Amy Criego; David B Dunger; Daniella Elleri; Mark L Evans; Elke Fröhlich-Reiterer; Sabine Hofer; Thomas Kapellen; Lalantha Leelarathna; Thomas R Pieber; Birgit Rami-Merhar; Viral N Shah; Judy Sibayan; Malgorzata E Wilinska; Roman Hovorka Journal: Diabetes Care Date: 2019-05-21 Impact factor: 19.112